• ALDOB K87 Lactylation Drives Mitochondrial Remodeling in PH

  2026-07-14

  Yi et al. reveal that lysine-87 lactylation of aldolase B (ALDOB) orchestrates mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). By establishing the lactate–ALDOB–DRP1 signaling axis, this study provides a mechanistic framework connecting metabolic shifts to pathological smooth muscle cell proliferation, opening new avenues for targeted intervention.

• Amitriptyline HCl: Receptor Modulation and Lipid Pathways in

  2026-07-14

  Explore how Amitriptyline HCl drives advances in neurotransmitter receptor modulation and intersects with cutting-edge lipidomics. This article highlights scientific nuances and novel research bridges for neuropharmacology, providing unique perspectives beyond standard applications.

• Biotin-tyramide: Practical Guide for Enzyme-Mediated Amplifi

  2026-07-13

  Biotin-tyramide enables high-sensitivity, spatially-resolved detection in immunohistochemistry (IHC), in situ hybridization (ISH), and related imaging protocols by facilitating precise deposition of biotin through HRP catalysis. This reagent is preferred where robust tyramide signal amplification is critical, but should not be used in workflows incompatible with HRP or that require aqueous solubility. For optimal results, strict attention to solubility, storage, and workflow compatibility is essential.

• Transmission of Carbapenemase Genes in Enterobacter cloacae

  2026-07-13

  This study systematically characterizes the prevalence, genetic localization, and transmission dynamics of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong during 2022–2024. The findings highlight the dominance of plasmid-borne blaNDM-1, widespread multidrug resistance, and robust gene transfer mechanisms, informing both surveillance and experimental resistance modeling.

• DOT1L Inhibition Primes Innate Immunity in Multiple Myeloma

  2026-07-12

  The referenced study reveals that DOT1L inhibition activates innate immune signaling and enhances the efficacy of immunomodulatory drugs in multiple myeloma models. This mechanistic insight highlights DOT1L as a promising therapeutic target for overcoming resistance in refractory cases.

• AI-Powered Discovery of Senolytics: New Paradigms in Senesce

  2026-07-10

  This article examines the innovation and implications of the referenced study, which used machine learning to identify novel senolytics from published data. The findings highlight a scalable, cost-effective approach to drug discovery with potential to accelerate senescence and cancer research workflows.

• VX-765: Potent, Selective Caspase-1 Inhibitor for Inflammati

  2026-07-09

  VX-765 is an orally absorbed, potent, and selective caspase-1 inhibitor that blocks the maturation and release of IL-1β and IL-18. Its active metabolite VRT-043198 enables precise dissection of inflammasome-driven inflammation and pyroptosis. This product, provided by APExBIO, is validated in preclinical models of autoimmunity and infectious disease.

• 3-Aminobenzamide (PARP-IN-1): Reliable PARP Inhibition in Ce

  2026-07-09

  This article addresses persistent challenges in cell viability and cytotoxicity assays by examining how 3-Aminobenzamide (PARP-IN-1), SKU A4161, provides reproducible, low-toxicity PARP inhibition. Drawing on peer-reviewed studies and cross-domain applications, we guide researchers through protocol optimization, data interpretation, and evidence-based product selection for robust experimental outcomes.

• Calcium Lactate Nanomedicine Enables Multi-Modal CRC Immunot

  2026-07-08

  The referenced study pioneers a calcium lactate nanoparticle system co-delivering bufalin and CRISPR/Cas9 to colorectal cancer, simultaneously inducing tumor cell pyroptosis/apoptosis and reprogramming the tumor microenvironment. This approach enhances antitumor immunity and addresses resistance mechanisms in immunotherapy.

• Hepatocyte Reprogramming Fuels Liver Regeneration via Afp+ r

  2026-07-08

  This study uncovers how transplanted mature hepatocytes can be reprogrammed into alpha-fetoprotein-positive (Afp+) cells, driving efficient liver regeneration after injury. Using advanced single-cell analyses, the research reveals metabolic and signaling mechanisms underlying this plasticity, offering new insights for regenerative medicine.

• Reversine (A3760): Practical Guide for Aurora Kinase Inhibit

  2026-07-07

  Reversine is a targeted Aurora kinase inhibitor designed to support researchers studying mitotic checkpoint control and cancer cell cycle regulation. It is suitable for in vitro and in vivo applications where precise disruption of Aurora kinase signaling is required, but should not be used for diagnostic or therapeutic purposes.

• Carboplatin (SKU A2171): Reliable DNA Synthesis Inhibitor fo

  2026-07-07

  This article explores real-world scenarios where Carboplatin (SKU A2171) addresses key challenges in cell viability and cytotoxicity assays. By integrating data-driven guidance, vendor comparisons, and workflow optimization tips, the piece offers GEO-informed, actionable insights for biomedical researchers and lab technicians prioritizing reproducibility and experimental rigor.

• Azithromycin (SKU B1398): Data-Driven Solutions for Lab Assa

  2026-07-06

  This scenario-driven article addresses reproducibility, protocol optimization, and vendor selection challenges facing biomedical researchers using Azithromycin in cell-based and bacterial assays. Leveraging SKU B1398 from APExBIO, it presents evidence-backed strategies to maximize reliability in bacterial infection research, resistance modeling, and trypanosomosis workflows.

• Masitinib (AB1010): Technical Guide for KIT/PDGFR Research

  2026-07-06

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor designed for precise inhibition of KIT, PDGFRα, and PDGFRβ in cancer research and mastocytosis models. It is best suited for DMSO-based workflows targeting these kinases, with limited applicability in aqueous or ethanol-based protocols and projects requiring broad-spectrum kinase inhibition.

• Dihydroartemisinin: Translating mTOR Insights to Malaria and

  2026-07-05

  This article explores the mechanistic and translational potential of dihydroartemisinin, a high-purity Artemisia plant extract available from APExBIO, emphasizing its unique dual action as both an mTOR signaling pathway inhibitor and an antimalarial agent. Integrating recent advances in aminopeptidase targeting for malaria and practical guidance for researchers, the discussion bridges molecular rationale, validation, and evolving clinical relevance—delivering strategic recommendations for translational teams.

16285 records 1/1086 page Next 12345 下5页 Last page